Engineered immune cells take on hard-to-treat lymphoma in early trial
NCT ID NCT06875063
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new treatment called GB5005 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goals are to check safety and see how many patients achieve complete remission. About 45 adults aged 18 to 70 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHIMERIC ANTIGEN RECEPTOR T-CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bing Xu
RECRUITINGXiamen, Fujian, 361000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a simple blood test spot lymphoma earlier?
- What happens years after CAR-T therapy? a study aims to find out
- Can a MALT1 blocker tame Hard-to-Treat lymphoma?